C4 Therapeutics Inc
NASDAQ:CCCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
US |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
US |
|
Metals X Ltd
ASX:MLX
|
AU |
|
Franklin Electric Co Inc
NASDAQ:FELE
|
US |
|
Graphite India Ltd
NSE:GRAPHITE
|
IN |
|
Alamo Group Inc
NYSE:ALG
|
US |
|
Brightspire Capital Inc
NYSE:BRSP
|
US |
|
FCS Software Solutions Ltd
NSE:FCSSOFT
|
IN |
|
Eldorado Gold Corp
TSX:ELD
|
CA |
|
S
|
Swiss Life Holding AG
XBER:SLW
|
CH |
Wall St Price Targets
CCCC Price Targets Summary
C4 Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CCCC is 11.8 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CCCC's stock price target?
Price Target
11.8
USD
According to Wall Street analysts, the average 1-year price target for
CCCC is 11.8 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.
What is the Revenue forecast for C4 Therapeutics Inc?
Projected CAGR
46%
Over the last 6 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 46%.